A randomized, double-blind, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of two different doses of vilaprisan (BAY 1002670) versus placebo in women with symptomatic endometriosis.(Protocol # 15792)

Study Details

The primary objective of this study is to assess the efficacy and safety of two doses of vilaprisan compared to placebo in women with symptomatic endometriosis.

The secondary objective of this study is to evaluate the safety and tolerability of two different doses of vilaprisan in women with symptomatic endometriosis

Learn More

ClinicalTrials.gov NCT number
NCT03573336

Principal Investigators

  • Scott Chudnoff, MD
Sponsor(s)
Bayer
Contact
Maureen Magnani, BSN, RN at 203-358-8879
or officeofresearch@stamhealth.org